Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib phase 3 trial in cDMARD-inadequate response rheumatoid arthritis
2012-002339-27Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Baricitinib 4 mg with Placebo (2 arms). Primary endpoint: ACR20 response at Week 12. Started Nov 2012; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-002339-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002339-27.